Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (4459)	8/11/2001 7:31:23 PM
From: rkrw	Read Replies (2) \| Respond to of 52153

The actelion drug swept the vote 10-0, how does it compare with the uthr drug? If both are approved, which is the winner in your opinion? There was an article recently in the Boston Globe about sildenafil and PPH and a group of physicians urging pfizer to sponsor a trial. Anectdotes are building that sildenafil may be a breakthrough drug for PPH. Since sildenafil is an already approved product, I'd be mindful of this when gauging the uthr drug's market potential. NEJM article from last year..... Sildenafil in Primary Pulmonary Hypertension Prasad S., Wilkinson J., Gatzoulis M. A. [ Full Text ] N Engl J Med 2000; 343:1342, Nov 2, 2000. Correspondence